Manno Daniela, Patterson Catriona, Drammeh Abdoulie, Tetteh Kevin, Kroma Mattu Tehtor, Otieno Godfrey Tuda, Lawal Bolarinde Joseph, Soremekun Seyi, Ayieko Philip, Gaddah Auguste, Kamara Abu Bakarr, Baiden Frank, Afolabi Muhammed Olanrewaju, Tindanbil Daniel, Owusu-Kyei Kwabena, Ishola David, Deen Gibrilla Fadlu, Keshinro Babajide, Njie Yusupha, Samai Mohamed, Lowe Brett, Robinson Cynthia, Leigh Bailah, Drakeley Chris, Greenwood Brian, Watson-Jones Deborah
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.
Vaccines (Basel). 2023 Aug 2;11(8):1317. doi: 10.3390/vaccines11081317.
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of antigens detected using a Luminex MAGPIX platform. Clinical malaria episodes after vaccinations were recorded as part of the trial safety monitoring. Binding antibody responses against the Ebola virus (EBOV) glycoprotein (GP) were measured 57 days post dose 1 and 21 days post dose 2 by ELISA and summarized as Geometric Mean Concentrations (GMCs). Geometric Mean Ratios (GMRs) were used to compare groups with different levels of exposure to malaria. Overall, 587 participants, comprising 188 (32%) adults (aged ≥ 18 years) and 399 (68%) children (aged 1-3, 4-11, and 12-17 years), were included in the analysis. There was no evidence that the anti-EBOV-GP antibody GMCs post dose 1 and post dose 2 differed between categories of previous malaria exposure. There was weak evidence that the GMC at 57 days post dose 1 was lower in participants who had had at least one episode of clinical malaria post dose 1 compared to participants with no diagnosed clinical malaria in the same period (GMR = 0.82, 95% CI: 0.69-0.98, -value = 0.02). However, GMC post dose 2 was not reduced in participants who experienced clinical malaria post-dose 1 and/or post-dose 2 vaccinations. In conclusion, the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in individuals with previous exposure to malaria and in those who experience clinical malaria after vaccination. This vaccine regimen is suitable for prophylaxis against Ebola virus disease in malaria-endemic regions.
我们评估了两剂Ad26.ZEBOV、MVA - BN - Filo埃博拉疫苗方案（两剂之间间隔56天）的免疫原性是否受到第1剂疫苗接种前疟疾暴露以及第1剂疫苗接种后和第2剂疫苗接种后即刻期间疟疾临床发作的影响。在塞拉利昂进行的一项埃博拉疫苗试验（ClinicalTrials.gov：NCT02509494）中，根据参与者对使用Luminex MAGPIX平台检测的一组抗原的抗体反应，将既往疟疾暴露分为低、中、高三个等级。接种疫苗后的临床疟疾发作情况作为试验安全性监测的一部分进行记录。在第1剂疫苗接种后57天和第2剂疫苗接种后21天，通过酶联免疫吸附测定（ELISA）测量针对埃博拉病毒（EBOV）糖蛋白（GP）的结合抗体反应，并汇总为几何平均浓度（GMCs）。使用几何平均比率（GMRs）比较疟疾暴露水平不同的组。总体而言，分析纳入了587名参与者，其中包括188名（32%）成年人（年龄≥18岁）和399名（68%）儿童（年龄1 - 3岁、4 - 11岁和12 - 17岁）。没有证据表明既往疟疾暴露类别之间第1剂疫苗接种后和第2剂疫苗接种后的抗EBOV - GP抗体GMCs存在差异。有微弱证据表明，与同期未诊断出临床疟疾的参与者相比，在第1剂疫苗接种后至少经历过一次临床疟疾发作的参与者在第1剂疫苗接种后57天的GMC较低（GMR = 0.82，95%置信区间：0.69 - 0.98，P值 = 0.02）。然而，在第1剂疫苗接种后和/或第2剂疫苗接种后经历临床疟疾的参与者中，第2剂疫苗接种后的GMC并未降低。总之，Ad26.ZEBOV、MVA - BN - Filo埃博拉疫苗方案在既往有疟疾暴露的个体以及接种疫苗后经历临床疟疾的个体中具有免疫原性。该疫苗方案适用于疟疾流行地区埃博拉病毒病的预防。
